Black Diamond Therapeutics (BDTX) Competitors $3.24 -0.14 (-4.14%) (As of 11/12/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BDTX vs. SPPI, CGEN, INBX, ITOS, CCCC, IGMS, TRDA, CRON, CRMD, and TRMLShould you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Spectrum Pharmaceuticals (SPPI), Compugen (CGEN), Inhibrx (INBX), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), IGM Biosciences (IGMS), Entrada Therapeutics (TRDA), Cronos Group (CRON), CorMedix (CRMD), and Tourmaline Bio (TRML). These companies are all part of the "medical" sector. Black Diamond Therapeutics vs. Spectrum Pharmaceuticals Compugen Inhibrx iTeos Therapeutics C4 Therapeutics IGM Biosciences Entrada Therapeutics Cronos Group CorMedix Tourmaline Bio Black Diamond Therapeutics (NASDAQ:BDTX) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Does the media favor BDTX or SPPI? In the previous week, Black Diamond Therapeutics had 15 more articles in the media than Spectrum Pharmaceuticals. MarketBeat recorded 15 mentions for Black Diamond Therapeutics and 0 mentions for Spectrum Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.13 beat Spectrum Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Black Diamond Therapeutics Positive Spectrum Pharmaceuticals Neutral Do insiders and institutionals have more ownership in BDTX or SPPI? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of Spectrum Pharmaceuticals shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 2.7% of Spectrum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, BDTX or SPPI? Spectrum Pharmaceuticals has higher revenue and earnings than Black Diamond Therapeutics. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-2.44Spectrum Pharmaceuticals$10.11M20.91-$75.40M-$0.36-2.86 Is BDTX or SPPI more profitable? Black Diamond Therapeutics' return on equity of -68.08% beat Spectrum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% Spectrum Pharmaceuticals N/A -218.44%-66.16% Which has more risk and volatility, BDTX or SPPI? Black Diamond Therapeutics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Do analysts prefer BDTX or SPPI? Black Diamond Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 378.40%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Spectrum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Spectrum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor BDTX or SPPI? Spectrum Pharmaceuticals received 436 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 62.36% of users gave Spectrum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% Spectrum PharmaceuticalsOutperform Votes48762.36% Underperform Votes29437.64% SummaryBlack Diamond Therapeutics beats Spectrum Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDTX vs. The Competition Export to ExcelMetricBlack Diamond TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.32M$3.10B$5.20B$8.93BDividend YieldN/A1.72%7.15%4.02%P/E Ratio-2.4447.81132.0718.10Price / SalesN/A305.381,383.5575.05Price / CashN/A176.1339.1736.30Price / Book1.885.166.186.01Net Income-$82.44M-$42.89M$117.66M$224.30M7 Day Performance-0.31%1.51%1.74%3.67%1 Month Performance-2.70%11.18%6.65%7.68%1 Year Performance82.02%44.94%42.94%32.56% Black Diamond Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDTXBlack Diamond Therapeutics3.1288 of 5 stars$3.24-4.1%$15.50+378.4%+82.0%$183.32MN/A-2.4490Earnings ReportShort Interest ↓Positive NewsSPPISpectrum PharmaceuticalsN/A$1.03flatN/AN/A$211.41M$10.11M-2.8686CGENCompugen2.0676 of 5 stars$1.78flatN/A+177.3%$158.84M$42.72M-17.8068Short Interest ↓News CoverageGap DownINBXInhibrx3.853 of 5 stars$16.32+0.7%N/A-13.2%$236.31M$1.63M0.00166Short Interest ↑ITOSiTeos Therapeutics3.1432 of 5 stars$9.66+4.2%N/A-3.9%$352.78M$12.60M-3.2290Analyst ForecastShort Interest ↓Gap UpCCCCC4 Therapeutics2.0263 of 5 stars$5.95-1.8%N/A+220.3%$420.01M$33.67M-3.50150Short Interest ↓IGMSIGM Biosciences4.5814 of 5 stars$12.59-3.4%N/A+151.7%$746.84M$2.13M-3.46190Earnings ReportAnalyst ForecastShort Interest ↓News CoverageTRDAEntrada Therapeutics1.7473 of 5 stars$19.91+0.5%N/A+19.0%$745.03M$129.01M12.52110Gap UpCRONCronos Group2.081 of 5 stars$1.93-3.5%N/A+9.7%$737.84M$87.24M-12.87356Short Interest ↓News CoverageGap UpCRMDCorMedix2.5196 of 5 stars$12.04+3.8%N/A+262.4%$730.59M$60,000.00-14.8630Short Interest ↓TRMLTourmaline Bio2.792 of 5 stars$28.46-1.0%N/A+59.1%$729.71MN/A-10.0944Earnings ReportAnalyst ForecastPositive News Related Companies and Tools Related Companies SPPI Competitors CGEN Competitors INBX Competitors ITOS Competitors CCCC Competitors IGMS Competitors TRDA Competitors CRON Competitors CRMD Competitors TRML Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDTX) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.